BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodell CB, Koch PD, Weissleder R. Screening for new macrophage therapeutics. Theranostics 2019;9:7714-29. [PMID: 31695796 DOI: 10.7150/thno.34421] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Rasaei R, Tyagi A, Rasaei S, Lee SJ, Yang SR, Kim KS, Ramakrishna S, Hong SH. Human pluripotent stem cell-derived macrophages and macrophage-derived exosomes: therapeutic potential in pulmonary fibrosis. Stem Cell Res Ther 2022;13:433. [PMID: 36056418 DOI: 10.1186/s13287-022-03136-z] [Reference Citation Analysis]
2 Tanaka T, Shiba T, Honda Y, Izawa K, Yasumi T, Saito MK, Nishikomori R. Induced Pluripotent Stem Cell-Derived Monocytes/Macrophages in Autoinflammatory Diseases. Front Immunol 2022;13:870535. [DOI: 10.3389/fimmu.2022.870535] [Reference Citation Analysis]
3 Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res 2022;41. [DOI: 10.1186/s13046-022-02272-x] [Reference Citation Analysis]
4 Soni SS, Rodell CB. Polymeric materials for immune engineering: Molecular interaction to biomaterial design. Acta Biomater 2021;133:139-52. [PMID: 33484909 DOI: 10.1016/j.actbio.2021.01.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
5 Lyadova I, Gerasimova T, Nenasheva T. Macrophages Derived From Human Induced Pluripotent Stem Cells: The Diversity of Protocols, Future Prospects, and Outstanding Questions. Front Cell Dev Biol 2021;9:640703. [PMID: 34150747 DOI: 10.3389/fcell.2021.640703] [Reference Citation Analysis]
6 Soni SS, Alsasa A, Rodell CB. Applications of Macrocyclic Host Molecules in Immune Modulation and Therapeutic Delivery. Front Chem 2021;9:658548. [PMID: 33889565 DOI: 10.3389/fchem.2021.658548] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kimm MA, Klenk C, Alunni-Fabbroni M, Kästle S, Stechele M, Ricke J, Eisenblätter M, Wildgruber M. Tumor-Associated Macrophages-Implications for Molecular Oncology and Imaging. Biomedicines 2021;9:374. [PMID: 33918295 DOI: 10.3390/biomedicines9040374] [Reference Citation Analysis]
8 Ma YS, Liu JB, Wu TM, Fu D. New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820945975. [PMID: 32799550 DOI: 10.1177/1073274820945975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Rodell CB, Baldwin P, Fernandez B, Weissleder R, Sridhar S, Dubach JM. Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating in vitro and in vivo Encapsulated Drug Delivery. Adv Ther (Weinh) 2021;4:2000125. [PMID: 33997266 DOI: 10.1002/adtp.202000125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Öhlinger K, Absenger-Novak M, Meindl C, Ober J, Fröhlich E. Different Sensitivity of Macrophages to Phospholipidosis Induction by Amphiphilic Cationic Drugs. Int J Mol Sci 2020;21:E8391. [PMID: 33182310 DOI: 10.3390/ijms21218391] [Reference Citation Analysis]
11 Koch PD, Pittet MJ, Weissleder R. The chemical biology of IL-12 production via the non-canonical NFkB pathway. RSC Chem Biol 2020;1:166-76. [PMID: 34458756 DOI: 10.1039/d0cb00022a] [Reference Citation Analysis]
12 Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering Macrophages for Cancer Immunotherapy and Drug Delivery. Adv Mater 2020;32:e2002054. [PMID: 32856350 DOI: 10.1002/adma.202002054] [Cited by in Crossref: 134] [Cited by in F6Publishing: 97] [Article Influence: 67.0] [Reference Citation Analysis]
13 Chen X, Chen M. Critical reviews of immunotheranostics. Theranostics 2020;10:7403-5. [PMID: 32642000 DOI: 10.7150/thno.48966] [Reference Citation Analysis]
14 Weissleder R, Pittet MJ. The expanding landscape of inflammatory cells affecting cancer therapy. Nat Biomed Eng 2020;4:489-98. [PMID: 32203281 DOI: 10.1038/s41551-020-0524-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
15 Rodell CB, Ahmed MS, Garris CS, Pittet MJ, Weissleder R. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics 2019;9:8426-36. [PMID: 31879528 DOI: 10.7150/thno.35434] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]